Sanofi plans to shrink, restructure Genzyme

Soon after Sanofi closed its $20 billion deal to buy Genzyme, CEO Chris Viehbacher (photo) made it clear that the storied biotech company would remain a standalone entity, reassuring loyalists by retaining its name and pushing ahead on its R&D efforts. Now the Boston Globe reports that only a scaled-down version of Genzyme will remain semi-independent as Sanofi absorbs the rest of the company. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.